{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T03:53:44Z","timestamp":1791345224759,"version":"4.3.1"},"reference-count":41,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2011,2,1]],"date-time":"2011-02-01T00:00:00Z","timestamp":1296518400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Stromal keratitis (SK) is a chronic immunopathological lesion of the eye caused by HSV-1 infection and a common cause of blindness in humans. The inflammatory lesions are primarily perpetuated by neutrophils with the active participation of CD4+ T cells. Therefore, targeting these immune cell types represents a potentially valuable form of therapy to reduce the severity of disease. Resolvin E1 (RvE1), an endogenous lipid mediator, was shown to promote resolution in several inflammatory disease models. In the current report, we determined whether RvE1 administration begun at different times after ocular infection of mice with HSV could influence the severity of SK lesions. Treatment with RvE1 significantly reduced the extent of angiogenesis and SK lesions that occurred. RvE1-treated mice had fewer numbers of inflammatory cells that included Th1 and Th17 cells as well as neutrophils in the cornea. The mechanisms by which RvE1 acts appear to be multiple. These included reducing the influx of neutrophils and pathogenic CD4+ T cells, increasing production of the anti-inflammatory cytokine IL-10, and inhibitory effects on the production of proinflammatory mediators and molecules, such as IL-6, IFN-\u03b3, IL-17, KC, VEGF-A, MMP-2, and MMP-9, that are involved in corneal neovascularization and SK pathogenesis. These findings are, to our knowledge, the first to show that RvE1 treatment could represent a novel approach to control lesion severity in a virally induced immunopathological disease.<\/jats:p>","DOI":"10.4049\/jimmunol.1003456","type":"journal-article","created":{"date-parts":[[2010,12,28]],"date-time":"2010-12-28T01:45:22Z","timestamp":1293500722000},"page":"1735-1746","source":"Crossref","is-referenced-by-count":122,"title":["Controlling Herpes Simplex Virus-Induced Ocular Inflammatory Lesions with the Lipid-Derived Mediator Resolvin E1"],"prefix":"10.1093","volume":"186","author":[{"given":"Naveen K","family":"Rajasagi","sequence":"first","affiliation":[{"name":"Comparative and Experimental Medicine, College of Veterinary Medicine, University of Tennessee , Knoxville, TN 37996"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pradeep B J","family":"Reddy","sequence":"additional","affiliation":[{"name":"Comparative and Experimental Medicine, College of Veterinary Medicine, University of Tennessee , Knoxville, TN 37996"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amol","family":"Suryawanshi","sequence":"additional","affiliation":[{"name":"Comparative and Experimental Medicine, College of Veterinary Medicine, University of Tennessee , Knoxville, TN 37996"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachin","family":"Mulik","sequence":"additional","affiliation":[{"name":"Comparative and Experimental Medicine, College of Veterinary Medicine, University of Tennessee , Knoxville, TN 37996"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per","family":"Gjorstrup","sequence":"additional","affiliation":[{"name":"Resolvyx Pharmaceuticals, Inc. , Cambridge, MA 02142"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry T","family":"Rouse","sequence":"additional","affiliation":[{"name":"Comparative and Experimental Medicine, College of Veterinary Medicine, University of Tennessee , Knoxville, TN 37996"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2011,2,1]]},"reference":[{"key":"2025032411043485200_r1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00003226-200101000-00001","article-title":"Herpes simplex virus epidemiology and ocular importance","volume":"20","author":"Liesegang","year":"2001","journal-title":"Cornea"},{"key":"2025032411043485200_r2","first-page":"441","article-title":"Ganciclovir ophthalmic gel, 0.15%: a valuable tool for treating ocular herpes","volume":"1","author":"Colin","year":"2007","journal-title":"Clin Ophthalmol"},{"key":"2025032411043485200_r3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S1462399404007604","article-title":"Herpetic eye disease: immunopathogenesis and therapeutic measures","volume":"6","author":"Deshpande","year":"2004","journal-title":"Expert Rev. Mol. Med."},{"key":"2025032411043485200_r4","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.survophthal.2008.12.004","article-title":"Management of herpes simplex virus stromal keratitis: an evidence-based review","volume":"54","author":"Knickelbein","year":"2009","journal-title":"Surv. Ophthalmol."},{"key":"2025032411043485200_r5","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2165\/00002018-200225010-00004","article-title":"Locally administered ocular corticosteroids: benefits and risks","volume":"25","author":"McGhee","year":"2002","journal-title":"Drug Saf."},{"key":"2025032411043485200_r6","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/nri2294","article-title":"Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators","volume":"8","author":"Serhan","year":"2008","journal-title":"Nat. Rev. Immunol."},{"key":"2025032411043485200_r7","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1084\/jem.192.8.1197","article-title":"Novel functional sets of lipid-derived mediators with antiinflammatory actions generated from omega-3 fatty acids via cyclooxygenase 2-nonsteroidal antiinflammatory drugs and transcellular processing","volume":"192","author":"Serhan","year":"2000","journal-title":"J. Exp. Med."},{"key":"2025032411043485200_r8","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1084\/jem.20020760","article-title":"Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals","volume":"196","author":"Serhan","year":"2002","journal-title":"J. Exp. Med."},{"key":"2025032411043485200_r9","doi-asserted-by":"crossref","first-page":"7671","DOI":"10.1073\/pnas.0409271102","article-title":"Resolvin E1, an endogenous lipid mediator derived from omega-3 eicosapentaenoic acid, protects against 2,4,6-trinitrobenzene sulfonic acid-induced colitis","volume":"102","author":"Arita","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2025032411043485200_r10","doi-asserted-by":"crossref","first-page":"4534","DOI":"10.4049\/jimmunol.181.7.4534","article-title":"Bone marrow-derived dendritic cells generated in the presence of resolvin E1 induce apoptosis of activated CD4+ T cells","volume":"181","author":"Vassiliou","year":"2008","journal-title":"J. Immunol."},{"key":"2025032411043485200_r11","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1016\/j.bbalip.2010.08.002","article-title":"Specialized pro-resolving lipid mediators in the inflammatory response: an update","volume":"1801","author":"Bannenberg","year":"2010","journal-title":"Biochim. Biophys. Acta"},{"key":"2025032411043485200_r12","doi-asserted-by":"crossref","first-page":"5601","DOI":"10.1167\/iovs.09-4468","article-title":"Dependence of resolvin-induced increases in corneal epithelial cell migration on EGF receptor transactivation","volume":"51","author":"Zhang","year":"2010","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"2025032411043485200_r13","doi-asserted-by":"crossref","first-page":"H153","DOI":"10.1152\/ajpheart.01057.2009","article-title":"Resolvin E1 protects the rat heart against reperfusion injury","volume":"299","author":"Keyes","year":"2010","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"2025032411043485200_r14","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1038\/ni.1627","article-title":"Resolvin E1 regulates interleukin 23, interferon-gamma and lipoxin A4 to promote the resolution of allergic airway inflammation","volume":"9","author":"Haworth","year":"2008","journal-title":"Nat. Immunol."},{"key":"2025032411043485200_r15","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/ibd.21029","article-title":"Resolvin E1, an endogenous lipid mediator derived from eicosapentaenoic acid, prevents dextran sulfate sodium-induced colitis","volume":"16","author":"Ishida","year":"2010","journal-title":"Inflamm. Bowel Dis."},{"key":"2025032411043485200_r16","doi-asserted-by":"crossref","first-page":"7021","DOI":"10.4049\/jimmunol.179.10.7021","article-title":"Resolvin E1 regulates inflammation at the cellular and tissue level and restores tissue homeostasis in vivo","volume":"179","author":"Hasturk","year":"2007","journal-title":"J. Immunol."},{"key":"2025032411043485200_r17","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/nm1591","article-title":"Increased dietary intake of \u03c9-3-polyunsaturated fatty acids reduces pathological retinal angiogenesis","volume":"13","author":"Connor","year":"2007","journal-title":"Nat. Med."},{"key":"2025032411043485200_r18","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1089\/jop.2010.0019","article-title":"Resolvin e1 improves tear production and decreases inflammation in a dry eye mouse model","volume":"26","author":"Li","year":"2010","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"2025032411043485200_r19","doi-asserted-by":"crossref","first-page":"836","DOI":"10.4049\/jimmunol.0901809","article-title":"The anti-inflammatory and proresolving mediator resolvin E1 protects mice from bacterial pneumonia and acute lung injury","volume":"184","author":"Seki","year":"2010","journal-title":"J. Immunol."},{"key":"2025032411043485200_r20","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0378-1135(01)00487-4","article-title":"Mechanisms of pathogenesis in herpetic immunoinflammatory ocular lesions","volume":"86","author":"Deshpande","year":"2002","journal-title":"Vet. Microbiol."},{"key":"2025032411043485200_r21","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.4049\/jimmunol.149.9.3035","article-title":"Predominance of Th1 cells in ocular tissues during herpetic stromal keratitis","volume":"149","author":"Niemialtowski","year":"1992","journal-title":"J. Immunol."},{"key":"2025032411043485200_r22","first-page":"1929","article-title":"Contribution of virus and immune factors to herpes simplex virus type I-induced corneal pathology","volume":"31","author":"Hendricks","year":"1990","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"2025032411043485200_r23","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.bbrc.2010.08.025","article-title":"Protective effect of resolvin E1 on the development of asthmatic airway inflammation","volume":"400","author":"Aoki","year":"2010","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2025032411043485200_r24","doi-asserted-by":"crossref","first-page":"14298","DOI":"10.1073\/pnas.0914730107","article-title":"Resolvin E1-induced intestinal alkaline phosphatase promotes resolution of inflammation through LPS detoxification","volume":"107","author":"Campbell","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2025032411043485200_r25","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1189\/jlb.0406295","article-title":"Depletion of MCP-1 increases development of herpetic stromal keratitis by innate immune modulation","volume":"80","author":"Kim","year":"2006","journal-title":"J. Leukoc. Biol."},{"key":"2025032411043485200_r26","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.4049\/jimmunol.158.3.1383","article-title":"On the essential involvement of neutrophils in the immunopathologic disease: herpetic stromal keratitis","volume":"158","author":"Thomas","year":"1997","journal-title":"J. Immunol."},{"key":"2025032411043485200_r27","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.exer.2005.05.001","article-title":"Involvement of IL-6 in the paracrine production of VEGF in ocular HSV-1 infection","volume":"82","author":"Biswas","year":"2006","journal-title":"Exp. Eye Res."},{"key":"2025032411043485200_r28","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1172\/JCI0215755","article-title":"Role of matrix metalloproteinase-9 in angiogenesis caused by ocular infection with herpes simplex virus","volume":"110","author":"Lee","year":"2002","journal-title":"J. Clin. Invest."},{"key":"2025032411043485200_r29","doi-asserted-by":"crossref","first-page":"6297","DOI":"10.4049\/jimmunol.180.9.6297","article-title":"IL-10 and natural regulatory T cells: two independent anti-inflammatory mechanisms in herpes simplex virus-induced ocular immunopathology","volume":"180","author":"Sarangi","year":"2008","journal-title":"J. Immunol."},{"key":"2025032411043485200_r30","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.4049\/jimmunol.153.5.2258","article-title":"Interleukin-10 treatment can suppress stromal keratitis induced by herpes simplex virus type 1","volume":"153","author":"Tumpey","year":"1994","journal-title":"J. Immunol."},{"key":"2025032411043485200_r31","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1038\/nature05877","article-title":"Resolvin E1 and protectin D1 activate inflammation-resolution programmes","volume":"447","author":"Schwab","year":"2007","journal-title":"Nature"},{"key":"2025032411043485200_r32","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.4049\/jimmunol.0902866","article-title":"A new strategy for the identification of novel molecules with targeted proresolution of inflammation properties","volume":"184","author":"Navarro-Xavier","year":"2010","journal-title":"J. Immunol."},{"key":"2025032411043485200_r33","doi-asserted-by":"crossref","first-page":"9828","DOI":"10.1128\/JVI.75.20.9828-9835.2001","article-title":"Contribution of vascular endothelial growth factor in the neovascularization process during the pathogenesis of herpetic stromal keratitis","volume":"75","author":"Zheng","year":"2001","journal-title":"J. Virol."},{"key":"2025032411043485200_r34","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.micinf.2005.03.003","article-title":"Early events in HSV keratitis\u2014setting the stage for a blinding disease","volume":"7","author":"Biswas","year":"2005","journal-title":"Microbes Infect."},{"key":"2025032411043485200_r35","doi-asserted-by":"crossref","first-page":"4743","DOI":"10.1167\/iovs.08-2462","article-title":"Anti-angiogenesis effect of the novel anti-inflammatory and pro-resolving lipid mediators","volume":"50","author":"Jin","year":"2009","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"2025032411043485200_r36","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/nm1551","article-title":"A brief history of T(H)17, the first major revision in the T(H)1\/T(H)2 hypothesis of T cell-mediated tissue damage","volume":"13","author":"Steinman","year":"2007","journal-title":"Nat. Med."},{"key":"2025032411043485200_r37","doi-asserted-by":"crossref","first-page":"5897","DOI":"10.4049\/jimmunol.169.10.5897","article-title":"IL-17 expression in human herpetic stromal keratitis: modulatory effects on chemokine production by corneal fibroblasts","volume":"169","author":"Maertzdorf","year":"2002","journal-title":"J. Immunol."},{"key":"2025032411043485200_r38","doi-asserted-by":"crossref","first-page":"5771","DOI":"10.4049\/jimmunol.180.9.5771","article-title":"IL-10: the master regulator of immunity to infection","volume":"180","author":"Couper","year":"2008","journal-title":"J. Immunol."},{"key":"2025032411043485200_r39","doi-asserted-by":"crossref","first-page":"4117","DOI":"10.1182\/blood-2007-12-129767","article-title":"Resolution-phase macrophages possess a unique inflammatory phenotype that is controlled by cAMP","volume":"112","author":"Bystrom","year":"2008","journal-title":"Blood"},{"key":"2025032411043485200_r40","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/S0002-9440(10)61777-4","article-title":"Control of stromal keratitis by inhibition of neovascularization","volume":"159","author":"Zheng","year":"2001","journal-title":"Am. J. Pathol."},{"key":"2025032411043485200_r41","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.preteyeres.2008.05.001","article-title":"Vascular endothelial growth factor in eye disease","volume":"27","author":"Penn","year":"2008","journal-title":"Prog. Retin. Eye Res."}],"container-title":["The Journal of Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jimmunol\/article-pdf\/186\/3\/1735\/61614863\/1003456.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jimmunol\/article-pdf\/186\/3\/1735\/61614863\/1003456.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T09:20:39Z","timestamp":1743153639000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jimmunol\/article\/186\/3\/1735\/7978094"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,2,1]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,2,1]]}},"URL":"https:\/\/doi.org\/10.4049\/jimmunol.1003456","relation":{},"ISSN":["0022-1767","1550-6606"],"issn-type":[{"value":"0022-1767","type":"print"},{"value":"1550-6606","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2011,2]]},"published":{"date-parts":[[2011,2,1]]}}}